Market Overview

Oppenheimer Initiates Outperform On Affimed, Sees $14/Share


In a report published Monday, Oppenheimer analyst Christopher Marai initiated coverage of Affimed NV (NASDAQ: AFMD) with an Outperform rating and a price target of $14.

Affimed is a clinical-stage biopharmaceutical company discovering and developing highly targeted cancer immunotherapies. The company is currently developing proprietary bispecific biologics (TandAbs), which redirect cells of the immune system to tumors for the treatment of cancer.

The company's lead candidate AFM13, a CD30xCD16A TandAb, redirects natural-killer (NK) cells to CD30-expressing lymphomas and is in phase 2 trials.

"We anticipate positive data for AFM13 in 4Q15 will lead to registration-worthy P2b trials. We recommend owning AFMD, viewing it as a lower-risk opportunity, as it brings together validated mechanisms-of-action, targets and commercial opportunities for each pipeline compound with upside in rapid routes to registration," analyst Christopher Marai stated.

In the report Oppenheimer noted, "We also believe that combination trials of AFM13 with checkpoint inhibitors (PD-1) could yield synergies and profound results that may be superior to nivolumab (anti-PD-1) single agent activity in HL, which yielded breakthrough designation. We anticipate that this could offer AFM13 a top-spot in a $400M+ annual HL market and upside in other CD30+ cancers."

Affimed's development pipeline also includes AFM11, a clinical-stage Phase I TandAb that redirects T-cells to CD19 expressing cells.

"Finally, AFM21, an EGFRvIII-directed TandAb (CD16 or CD3), despite being clinically derisked in our view, remains early in development and upside to our price target at this time," Marai added.

Latest Ratings for AFMD

Jun 2020SVB LeerinkMaintainsOutperform
Mar 2019SVB LeerinkInitiates Coverage OnOutperform
Aug 2018JefferiesUpgradesHoldBuy

View More Analyst Ratings for AFMD
View the Latest Analyst Ratings


Related Articles (AFMD)

View Comments and Join the Discussion!

Posted-In: OppenheimerAnalyst Color Initiation Analyst Ratings

Latest Ratings

GRAWells FargoMaintains53.0
NSAWells FargoMaintains37.0
NKLADeutsche BankMaintains29.0
WHRDeutsche BankMaintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at